Opinion
Big pharmas are having a good year so far in terms of FDA approvals.
Incyte has been at the forefront of the IDO race with its candidate epacadostat.
Rumor is there’s a new approach to fighting cancer in town.
The former Biogen CEO is making waves at his new venture, Vir Biotechnology.
The drug developed by Nogra always seemed like a longshot, but Celgene management talked it up over the years as it advanced.
A look at how the gene therapy approvals may end up confusing payers, lawmakers, and the general public at a time when the industry desperately needs clarity.
Halozyme’s Enhanze drug delivery technology just won it a $105 million upfront payment from Bristol-Myers Squibb.
Kare Schultz will become Teva’s fourth CEO in a decade, and its second outsider.
Alnylam’s victory with Patisiran in familial amyloid polyneuropathy (FAP) is significant for more than just the company and its patients.